Tirzepatide weight loss at 3 months: what the data actually shows

What did @courtneyannklang actually say?

After three months on tirzepatide, Courtney reports losing 33.4 pounds and is receiving her fourth dose at the 7.5 mg level. She says she's hit a frustrating plateau, fluctuating within a "three pound difference for like a couple of weeks," and plans to stay at 7.5 mg rather than increasing. She's also honest about weighing herself daily and admits it's affecting her mental state when the number ticks up even slightly.

That last part is worth paying attention to. Most of this video isn't a dramatic transformation reveal. It's someone grappling with the psychological weight of tracking weight, which is arguably more useful to viewers than the number itself. She's doing the basics: drinking water, eating enough, going to the gym. No miracle framing here.

Does the science back this up?

Yes, broadly. A 33-pound loss over three months is on the higher end of what trials show, but it's not outside the realm of documented outcomes, especially for someone early in treatment.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on tirzepatide 15 mg lost an average of 20.9% of body weight over 72 weeks. At 7.5 mg, the average was around 14.4% over the same period. Courtney's three-month results are faster than trial averages, but early weight loss on GLP-1 and GIP receptor agonists tends to front-load, meaning the first few months often produce steeper drops before the body adapts and loss slows.

The plateau she describes is also well-documented. As body weight decreases, so does total daily energy expenditure, and adaptive thermogenesis kicks in. This isn't failure; it's physiology. Research by Leibel et al. (1995, New England Journal of Medicine) showed that weight loss consistently triggers metabolic compensation, which is exactly what she's experiencing.

What did they get wrong (or right)?

Mostly right, with one thing worth flagging. Courtney says she's "down almost like 35 pounds in three weeks months," catching herself mid-slip. That's just a verbal stumble, not a factual error. No exaggerated claims, no promises that tirzepatide will work this way for everyone.

What she gets right: staying at a dose that's working rather than chasing higher doses is actually sound thinking. More isn't always better with tirzepatide. The dose-response curve flattens, and side effects, particularly gastrointestinal ones, increase with dose escalation. The SURMOUNT-1 data showed diminishing returns at higher doses relative to tolerability burden.

The daily weighing habit is worth a harder look. Research by Pacanowski and Levitsky (2015, Journal of Obesity) found that daily weigh-ins can support long-term weight management for some people, but the same research flags that emotional reactivity to scale fluctuations, exactly what Courtney describes, can trigger disordered eating patterns in vulnerable individuals. She's right to question it.

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which distinguishes it mechanically from semaglutide-only drugs. This dual action appears to produce stronger weight loss outcomes on average, though individual response varies considerably. Your results at 7.5 mg could look nothing like Courtney's, and that's not a failure of the drug or of you.

A few things this video doesn't address that matter clinically:

• Compounded tirzepatide (referenced in her hashtags as "tirzepatidecompound") is not the same as FDA-approved Zepbound or Mounjaro. Compounded versions are not FDA-approved and may differ in purity, concentration, and excipients. The FDA has issued warnings about this.
• Weight loss of this pace raises questions about lean mass preservation. Losing muscle alongside fat is common without adequate protein intake and resistance training. She mentions the gym, which helps, but protein targets matter here.
• Plateaus at three months are normal, not a sign the medication stopped working.

The bottom line

Courtney's three-month tirzepatide update is one of the more grounded GLP-1 videos circulating on TikTok right now. She's not selling anything, not overclaiming, and she's being candid about the mental health friction of obsessive scale-checking. The weight loss she reports is plausible given the clinical literature, if on the faster end. The plateau is real and expected. The insight about needing a "mindset shift" around daily weigh-ins is, frankly, better advice than most telehealth apps give their patients on this topic.